Maravai LifeSciences Holdings, Inc.
Financials
Valuation Metrics
Maravai LifeSciences Holdings, Inc.'s Market Cap is $2.57B. At end of 2025 it was $471M. Ranked #1821 of 3,121 in US market (top 58%), #663 of 1,463 on NASDAQ (top 45%), #110 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.57B | US#1,821/3,121 Sec#110/266 |
| Revenue | $209M | US#2,567/3,121 Sec#109/266 |
| Net Income | $-77M | US—/3,121 Sec—/266 |
| Total Assets | $604M | US#2,698/3,121 Sec#142/266 |
| Net Assets | $205M | US#2,677/3,121 Sec#192/266 |
| Employees | 415 | US#2,329/3,121 Sec#91/266 |
| Value | ||
| P/B | 12.56x | US#2,704/3,121 Sec#203/266 |
| P/S | 12.31x | US#2,754/3,121 Sec#120/266 |
| FCF Yield | -1.37% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -37.82% | US#2,613/3,121 Sec#128/266 |
| ROA | -12.82% | US#2,712/3,121 Sec#108/266 |
| Op. Margin | 46.02% | US#170/3,121 Sec#8/266 |
| Revenue Growth | -3.28% | US#2,421/3,121 Sec#141/266 |
| Financial Health | ||
| Debt Ratio | 121.28% | US#1,271/3,121 Sec#173/266 |
| Total Debt | $177M | US#2,289/3,121 Sec#97/266 |
| FCF | $-35M | US#2,487/3,121 Sec#103/266 |
| Cash | $70M | US#2,426/3,121 Sec#205/266 |
| Current Ratio | 4.05x | US#573/3,121 Sec#164/266 |
| Performance | ||
| 1Y Return | 142.01% | US#100/3,121 Sec#42/266 |
| 1M Return | -3.46% | US#51/3,121 Sec#10/266 |
| From 52W High | -26.01% | US#1,678/3,121 Sec#128/266 |
| 1Y MDD | -29.60% | US#1,384/3,121 Sec#88/266 |
| Trading | ||
| Volume | 2,382,622 shares | US#672/3,121 Sec#65/266 |
| Trading Value | $17M | US#1,909/3,121 Sec#149/266 |
| Per Share | ||
| EPS | $-0.21 | US—/3,121 Sec—/266 |
| BPS | $0.55 | US#2,750/3,121 Sec#217/266 |
Company Info
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.